Journal Scans
Factors Associated With Clinical Benefit From Epidermal Growth Factor Receptor Inhibitors in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Predicting Benefit From EGFR Inhibitors in HNSCC
EEW Cohen, AB Halpern, K Kasza, M Kocherginsky, R Williams, EE Vokes
20090901
2009 Oct 1
Oral Oncol
Factors Associated With Clinical Benefit From Epidermal Growth Factor Receptor Inhibitors in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Oral Oncol. 2009 Oct 1;45(10), EEW Cohen, AB Halpern, K Kasza, M Kocherginsky, R Williams, EE Vokes
TAKE-HOME MESSAGE
Abstract
Abstract
Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have demonstrated reproducible response rates of 5–15% in treatment of squamous cell carcinomas of the head and neck (SCCHN). The subset of patients that benefits most from these agents remains unknown. We reviewed individual patient data from five clinical trials of erlotinib, lapatinib, or gefitinib to determine if there are clinical characteristics that are associated with clinical benefit defined as complete...
